Breaking News
A vaccine that blocks the effects of fentanyl, including overdoses, is scheduled for Phase I human trials in the Netherlands in early 2026 to assess its safety.
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been given an expanded label by the U.S. Food and Drug Administration to include use in adults with progressive pulmonary fibrosis.
BioTrending
- By Amy Scanlin, MS
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
- By Diane L.M. Cook
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.
- By Jim Trageser
While still in their early stages of research, FDA has approved more than a dozen complement inhibitors to treat various conditions, and there is hope that more will be on the horizon to treat others.
- By Trudie Mitschang
Virtual hospitals bring hospital-level care directly to patients' homes, representing a transformative step in healthcare delivery.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
